Arrowgrass Capital Partners (US)’s Bristol-Myers Squibb BMY Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-21,224	Closed	-$1.08M	–	76
2019 Q3	$1.08M	Sell	21,224 -12,471	-37%	-$586K	0.08%	154
2019 Q2	$1.53M	Buy	33,695 +5,496	+19%	+$256K	0.04%	280
2019 Q1	$1.34M	Buy	+28,199	New	+$1.4M	0.04%	278
2017 Q3	–	Sell	-51,566	Closed	-$3.01M	–	580
2017 Q2	$2.87M	Sell	51,566 -16,723	-24%	-$910K	0.02%	444
2017 Q1	$3.71M	Buy	+68,289	New	+$3.75M	0.04%	364
2016 Q4	–	Sell	-3,265	Closed	-$178K	–	537
2016 Q3	$176K	Buy	3,265 +2,504	+329%	+$161K	﹤0.01%	428
2016 Q2	$56K	Sell	761 -550	-42%	-$38.9K	﹤0.01%	411
2016 Q1	$84K	Sell	1,311 -11,042	-89%	-$696K	﹤0.01%	383
2015 Q4	$850K	Sell	12,353 -7,363	-37%	-$487K	0.01%	338
2015 Q3	$1.17M	Buy	+19,716	New	+$1.25M	0.02%	327
2015 Q1	–	Sell	-231,998	Closed	-$14.5M	–	421
2014 Q4	$13.7M	Buy	+231,998	New	+$13.1M	0.24%	58

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s BMY Position: Q4 2019 in Review

Arrowgrass Capital Partners (US) sold out of Bristol-Myers Squibb (BMY) in Q4 2019, closing a stake of 21,224 shares — an estimated $1.08M sold.

Arrowgrass Capital Partners (US) first reported a position in BMY in Q4 2014 and held it in 11 quarters. The position peaked at $13.7M in Q4 2014. 2,218 funds tracked by Wall St. Rank hold BMY as of Q4 2019.

Arrowgrass Capital Partners (US) reported no remaining Bristol-Myers Squibb position as of Q4 2019 after selling out during the quarter.
Arrowgrass Capital Partners (US) sold 21,224 Bristol-Myers Squibb shares in Q4 2019, an estimated $1.08M.
Arrowgrass Capital Partners (US) first reported a position in Bristol-Myers Squibb in Q4 2014 and held it in 11 quarters.
Arrowgrass Capital Partners (US)'s Bristol-Myers Squibb position peaked at $13.7M in Q4 2014.
2,218 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2019.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q4 2019, filed 14 Feb 2020.